

2602 S. 24th Street . Phoenix, AZ 85034 Tel 602 759 1245 . Fax 602 759 8331 . www.CyrexLabs.com ACCESSION #: 23-082900 REQUISITION #: T01234567 SAMPLE TYPE: Serum DOCTOR / PATIENT ID: PAGES: 1 of 2 DATE COLLECTED: 1/01/2023 DATE RECEIVED: 1/01/2023 DATE OF REPORT: 1/01/2023

## PRACTITIONER

## DEMO, DOCTOR

2602 S. 24th Street Phoenix, AZ 85034

## PATIENT

Name: SAMPLE, PATIENT DB: 1/1/2000 Gender: F

TEST	RESULT				
Alzheimer's LINX™ - Alzheimer's-Associated Immune Reactivity **	IN RANGE (Normal)	EQUIVOCAL*	OUT OF RANGE	REFERENCE (ELISA Index)	
Brain Proteins					
Tau Protein	0.56			0.0-1.2	
Amyloid-Beta Peptide	0.86			0.1-1.4	
Rabaptin-5 + Presenilin	0.68			0.0-1.4	
Alpha-Synuclein			2.20	0.4-1.7	
Growth Factors					
Beta Nerve Growth Factor	0.76			0.3-1.5	
Brain Derived Neurotrophic Factor	0.57			0.0-1.0	
Neurotrophins	0.58			0.5-1.8	
Somatotropin			1.89	0.1-1.8	
Enteric Nerve, Enzymes and Neurological Peptides					
Enteric Nerve + Vasoactive Intestinal Peptide			1.03	0.0-1.0	
Transglutaminases	0.68			0.2-1.3	
Pathogens					
Oral Pathogens	0.36			0.2-1.1	
Enterococcus faecalis	0.85			0.4-1.8	
Escherichia coli CDT + Salmonella CDT	1.04			0.3-1.7	
Campylobacter jejuni CDT	0.88			0.0-1.7	
Herpes Type-1		1.54		0.2-1.8	
Chemicals					
Aluminums	0.59			0.4-1.5	
Dinitrophenyl	0.54			0.6-1.9	
Ethyl + Methyl Mercury	0.40			0.3-1.3	
Phthalates		1.90		0.4-1.9	
Foods Cross-Reactive to Amyloid Beta					
Egg Yolk, Raw + Cooked			2.48	0.0-2.1	

Download your Patient Educational Guide at https://www.cyrexlabs.com/docs/linx-peg.pdf

 $^{**}$  For details on the method of cooking, please see specification sheets. All analytes are tested for IgG .

\* Reference ranges are calculated based on the mean  $\pm 2$  standard deviations (SD). Results > 1 SD, and <2 SDs above the mean are considered to be equivocal. An equivocal result represents the range between negative and suspicious low positive results. Results >2 SDs are considered out of range, and positive.

Gopal Krishnan, PhD, Laboratory Director

Cyrex Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Test result data on its own does not constitute a diagnosis of any disease, including Alzheimer's. Only a physician or qualified healthcare professional should interpret the significance of a clinical lab test or make a diagnosis. This test was developed and its performance characteristics determined by Cyrex Laboratories, LLC. This test is a "lab developed test" and therefore not subject to clearance or approval by the US Food and Drug Administration. The names and titles of tests and arrays are for reference purposes only.



2602 S. 24th Street . Phoenix, AZ 85034 Tel 602 759 1245 . Fax 602 759 8331 . www.CyrexLabs.com ACCESSION #: 23-082900 REQUISITION #: T01234567 SAMPLE TYPE: Serum DOCTOR / PATIENT ID: PAGES: 1 of 2 DATE COLLECTED: 1/01/2023 DATE RECEIVED: 1/01/2023 DATE OF REPORT: 1/01/2023

## PRACTITIONER

DEMO, DOCTOR

2602 S. 24th Street Phoenix, AZ 85034 PATIENT

Name: SAMPLE, PATIENT DB: 1/1/2000 Gender: F

Lentil Lectin + Pea Lectin	0.92			0.4-1.2
Tuna, Canned		0.96		0.0-1.0
Hazelnut Vicilin + Cashew Vicilin	1.52			0.5-2.1
Scallops + Squid	1.45			0.2-2.0
Caseins		2.79		0.0-3.0
Alpha-Gliadin + Gliadin Toxic Peptide			2.83	0.3-2.1
Non-Gluten Wheat Proteins		1.59		0.3-1.6
Blood Brain Barrier and Neurofilaments				
Blood-Brain Barrier Protein + Claudin-5		1.37		0.2-1.4
Aquaporins	0.48			0.2-1.0
Neurofilament Proteins	1.17			0.4-2.1

Download your Patient Educational Guide at https://www.cyrexlabs.com/docs/linx-peg.pdf

\*\* For details on the method of cooking, please see specification sheets. All analytes are tested for IgG .

\* Reference ranges are calculated based on the mean ±2 standard deviations (SD). Results > 1 SD, and <2 SDs above the mean are considered to be equivocal. An equivocal result represents the range between negative and suspicious low positive results. Results >2 SDs are considered out of range, and positive.

Gopal Krishnan, PhD, Laboratory Director

Cyrex Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Test result data on its own does not constitute a diagnosis of any disease, including Alzheimer's. Only a physician or qualified healthcare professional should interpret the significance of a clinical lab test or make a diagnosis. This test was developed and its performance characteristics determined by Cyrex Laboratories, LLC. This test is a "lab developed test" and therefore not subject to clearance or approval by the US Food and Drug Administration. The names and titles of tests and arrays are for reference purposes only.